Johns Hopkins Clinical Trials Learning Session

Johns Hopkins SKCCC clinical trials will be presented and discussed by the speakers identified below:

PROMISE REGISTRY: The purpose of the PROMISE registry is to learn more about the role genes play in improving outcomes for prostate cancer patients. Knowing this information could make a big difference in the type of treatment available to you “now, and in the future.” Participants will receive a free genetic test.

STEP-UP Trial: This is a phase II trial for men with prostate cancer that has spread to the bones (metastatic). The trial studies the effect of changing high-dose testosterone and enzalutamide compared with enzalutamide alone. Past studies have shown that testosterone alone may help stop the growth of prostate cancer cells. It may also improve the disease response to enzalutamide.

Study Assessing the Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With mCRPC: Previous studies, which injected high dose testosterone therapy into the muscle of men with metastatic castration-resistant prostate cancer (mCRPC), suggested that high serum levels of testosterone may improve prostate cancer treatment response. This study will help doctors understand if treating mCRPC men with the highest “FDA approved dose of oral testosterone therapy” will have a similar effect as receiving injected testosterone therapy.



Keith Crawford, MD, PhD
Director of Clinical Trials and Patient Education, PHEN

Catherine Marshall, MD, MPH
Assistant Professor
Johns Hopkins University School of Medicine

Samuel Denmeade, MD
Johns Hopkins University School of Medicine

Leave a Reply

Your email address will not be published. Required fields are marked *